RE:RE:RE:RE:RE:RE:RE:RE:RE:2 weeks: It’s all it took for Merck to get AA
Eog, I hope you are right, but why would their analyst, who most likely knows more than anyone on this board push revenues out to 2026 and reduce the price target right after the PP? When is the last time you have seen TLT talk about revenue in 2023. Why would Uddin say he felt TLD was a better option then Keytruda, then lower his price target and push out the launch to 2026? Don't you think there is a reason behind it. I hope it is a molehill, but you can't just ignore the facts and pray...